PMID- 7507009
OWN - NLM
STAT- MEDLINE
DCOM- 19940224
LR  - 20190813
IS  - 0300-0664 (Print)
IS  - 0300-0664 (Linking)
VI  - 39
IP  - 4
DP  - 1993 Oct
TI  - Growth hormone dose regimens in adult GH deficiency: effects on biochemical 
      growth markers and metabolic parameters.
PG  - 403-8
AB  - OBJECTIVE: We examined the effects of different doses of GH on insulin-like 
      growth factor I (IGF-I), IGF binding protein 3 (IGFBP-3), body composition, 
      energy expenditure, and various metabolites in GH deficient adults, in order to 
      approach a metabolically appropriate GH dosage in young GH deficient adults. 
      DESIGN: Ten GH deficient patients (age 21-43) were studied after 4 weeks without 
      GH followed by three consecutive 4-week periods, where the patients received in a 
      fixed order GH 1, 2 and 4 IU/m2 s.c. per day. At the end of each period the 
      patients were hospitalized for a 24-hour examination. RESULTS: Mean 24-hour 
      levels of GH (mIU/l) were 2.7 +/- 0.3 (0 GH), 7.2 +/- 0.9 (1), 10.8 +/- 1.5 (2) 
      and 18.9 +/- 2.7 (4 IU/m2) (mean +/- SEM) (P < 0.01). Likewise, IGF-I levels 
      increased dose dependently from 61 +/- 21 to 206 +/- 65, 260 +/- 70 and 468 +/- 
      171 micrograms/l (P < 0.05); serum IGF-I in an age and sex matched control group 
      was 248 +/- 25 micrograms/l. Corresponding serum IGFBP-3 levels also increased 
      from 1860 +/- 239 to 3261 +/- 379, 3762 +/- 434 and 4384 +/- 652 micrograms/l (P 
      = 0.01) respectively. Significant increases in diurnal serum insulin levels after 
      4 IU/m2 were recorded, whereas plasma glucose levels remained unchanged. Lipid 
      intermediates increased dose independently during GH administration. GH caused a 
      significant increase in resting energy expenditure, whereas the respiratory 
      exchange ratio was unaltered. Fat mass was increased without GH therapy and 
      decreased during the study. Four patients made complaints during 4 IU/m2 GH 
      administration, probably related to GH induced fluid retention. CONCLUSION: Based 
      primarily on IGF-I and IGFBP-3 levels our data suggest that a GH replacement dose 
      in young GH deficient adults in the order of 1-2 IU/m2 per day is adequate. This 
      is a relatively low dose as compared to dose regimens in children and 
      adolescents.
FAU - Moller, J
AU  - Moller J
AD  - Medical Department M (Endocrinology and Diabetes), Aarhus Kommunehospital, 
      Denmark.
FAU - Jorgensen, J O
AU  - Jorgensen JO
FAU - Lauersen, T
AU  - Lauersen T
FAU - Frystyk, J
AU  - Frystyk J
FAU - Naeraa, R W
AU  - Naeraa RW
FAU - Orskov, H
AU  - Orskov H
FAU - Christiansen, J S
AU  - Christiansen JS
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
RN  - 0 (Blood Glucose)
RN  - 0 (Carrier Proteins)
RN  - 0 (Insulin)
RN  - 0 (Insulin-Like Growth Factor Binding Proteins)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - 9002-72-6 (Growth Hormone)
SB  - IM
CIN - Clin Endocrinol (Oxf). 1993 Oct;39(4):401-2. PMID: 8287566
MH  - Adult
MH  - Blood Glucose/drug effects
MH  - Body Composition/drug effects
MH  - Carrier Proteins/blood/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Energy Metabolism/drug effects
MH  - Female
MH  - Growth Hormone/*administration & dosage/*deficiency/pharmacology
MH  - Humans
MH  - Insulin/blood
MH  - Insulin-Like Growth Factor Binding Proteins
MH  - Insulin-Like Growth Factor I/*drug effects/metabolism
MH  - Male
EDAT- 1993/10/01 00:00
MHDA- 1993/10/01 00:01
CRDT- 1993/10/01 00:00
PHST- 1993/10/01 00:00 [pubmed]
PHST- 1993/10/01 00:01 [medline]
PHST- 1993/10/01 00:00 [entrez]
AID - 10.1111/j.1365-2265.1993.tb02386.x [doi]
PST - ppublish
SO  - Clin Endocrinol (Oxf). 1993 Oct;39(4):403-8. doi: 
      10.1111/j.1365-2265.1993.tb02386.x.